DISHMAN CARBOGEN AMCIS | SANDU PHARMA | DISHMAN CARBOGEN AMCIS/ SANDU PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -20.7 | 38.4 | - | View Chart |
P/BV | x | 0.6 | 1.4 | 46.3% | View Chart |
Dividend Yield | % | 0.0 | 1.4 | - |
DISHMAN CARBOGEN AMCIS SANDU PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN CARBOGEN AMCIS Mar-24 |
SANDU PHARMA Mar-24 |
DISHMAN CARBOGEN AMCIS/ SANDU PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 283 | 85 | 332.9% | |
Low | Rs | 113 | 49 | 231.1% | |
Sales per share (Unadj.) | Rs | 166.8 | 69.6 | 239.5% | |
Earnings per share (Unadj.) | Rs | -9.8 | 1.5 | -647.1% | |
Cash flow per share (Unadj.) | Rs | 10.0 | 2.1 | 474.3% | |
Dividends per share (Unadj.) | Rs | 0 | 0.80 | 0.0% | |
Avg Dividend yield | % | 0 | 1.2 | 0.0% | |
Book value per share (Unadj.) | Rs | 358.9 | 42.0 | 854.2% | |
Shares outstanding (eoy) | m | 156.78 | 9.66 | 1,623.0% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.2 | 1.0 | 123.4% | |
Avg P/E ratio | x | -20.2 | 44.3 | -45.7% | |
P/CF ratio (eoy) | x | 19.7 | 31.7 | 62.3% | |
Price / Book Value ratio | x | 0.6 | 1.6 | 34.6% | |
Dividend payout | % | 0 | 52.9 | -0.0% | |
Avg Mkt Cap | Rs m | 31,059 | 647 | 4,798.3% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 12,082 | 101 | 11,994.0% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 26,158 | 673 | 3,887.8% | |
Other income | Rs m | 508 | 4 | 11,978.8% | |
Total revenues | Rs m | 26,666 | 677 | 3,938.6% | |
Gross profit | Rs m | 2,578 | 23 | 11,227.4% | |
Depreciation | Rs m | 3,109 | 6 | 53,320.8% | |
Interest | Rs m | 1,200 | 1 | 190,428.6% | |
Profit before tax | Rs m | -1,223 | 21 | -5,897.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 312 | 6 | 5,096.4% | |
Profit after tax | Rs m | -1,535 | 15 | -10,503.1% | |
Gross profit margin | % | 9.9 | 3.4 | 288.8% | |
Effective tax rate | % | -25.5 | 29.5 | -86.5% | |
Net profit margin | % | -5.9 | 2.2 | -270.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,282 | 223 | 8,645.0% | |
Current liabilities | Rs m | 25,547 | 106 | 24,008.3% | |
Net working cap to sales | % | -24.0 | 17.3 | -138.2% | |
Current ratio | x | 0.8 | 2.1 | 36.0% | |
Inventory Days | Days | 41 | 66 | 62.1% | |
Debtors Days | Days | 6 | 264 | 2.4% | |
Net fixed assets | Rs m | 76,424 | 301 | 25,380.9% | |
Share capital | Rs m | 314 | 97 | 324.6% | |
"Free" reserves | Rs m | 55,961 | 309 | 18,091.7% | |
Net worth | Rs m | 56,275 | 406 | 13,863.2% | |
Long term debt | Rs m | 2,456 | 0 | - | |
Total assets | Rs m | 95,706 | 524 | 18,259.3% | |
Interest coverage | x | 0 | 33.9 | -0.1% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.3 | 1.3 | 21.3% | |
Return on assets | % | -0.3 | 2.9 | -12.0% | |
Return on equity | % | -2.7 | 3.6 | -75.8% | |
Return on capital | % | 0 | 5.3 | -0.7% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 3,187 | 0 | - | |
Fx outflow | Rs m | 327 | 0 | - | |
Net fx | Rs m | 2,860 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 3,840 | 8 | 50,522.4% | |
From Investments | Rs m | -2,295 | -13 | 17,560.8% | |
From Financial Activity | Rs m | -222 | -7 | 3,059.4% | |
Net Cashflow | Rs m | 1,323 | -13 | -10,400.9% |
Indian Promoters | % | 59.3 | 42.9 | 138.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 9.4 | 0.0 | 93,900.0% | |
FIIs | % | 8.2 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.7 | 57.1 | 71.2% | |
Shareholders | 55,280 | 10,246 | 539.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DISHMAN CARBOGEN AMCIS With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | DISHMAN CARBOGEN AMCIS | SANDU PHARMA | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -3.22% | 0.61% | -0.28% |
1-Month | 30.28% | 6.33% | -0.94% |
1-Year | 37.27% | -14.42% | 45.03% |
3-Year CAGR | 0.11% | 8.83% | 19.07% |
5-Year CAGR | 11.11% | 30.43% | 25.81% |
* Compound Annual Growth Rate
Here are more details on the DISHMAN CARBOGEN AMCIS share price and the SANDU PHARMA share price.
Moving on to shareholding structures...
The promoters of DISHMAN CARBOGEN AMCIS hold a 59.3% stake in the company. In case of SANDU PHARMA the stake stands at 42.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of DISHMAN CARBOGEN AMCIS and the shareholding pattern of SANDU PHARMA.
Finally, a word on dividends...
In the most recent financial year, DISHMAN CARBOGEN AMCIS paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
SANDU PHARMA paid Rs 0.8, and its dividend payout ratio stood at 52.9%.
You may visit here to review the dividend history of DISHMAN CARBOGEN AMCIS, and the dividend history of SANDU PHARMA.
For a sector overview, read our pharmaceuticals sector report.
After opening the day marginally lower, Indian benchmark indices reversed the trend as the session progressed and ended the day higher.